Managingip.com

CRISPR interference decision, Center for Intellectual Property Understanding, Alibaba, Section 101, Northern District of California – the week in IP

The USPTO has ruled there is “no interference in fact” in the closely-watched dispute over CRISPR patents between the University of California and the Broad Institute, reports MIT Technology Review.
Morningstar

GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World's First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational ...

The first patient, who received GEB-101 in May 2025, has been discharged from the collaborating hospital with no observable adverse event. This trial marks the world's first clinical study of an in ...
FOX8 Cleveland

Excision BioTherapeutics Receives FDA Fast Track Designation for EBT-101, a First-in-Class CRISPR-Based Gene Therapy Candidate to Functionally Cure HIV-1

EBT-101 is a potentially curative, one-time CRISPR-based treatment which makes two cuts in integrated retroviral DNA to remove large portions of the HIV genome and prevent HIV from escaping and ...
Precision Medicine Online

GenEditBio to Kick Off US Trial of CRISPR Gene-Edited Therapy for Corneal Dystrophy

The firm plans to enroll US patients into the trial of GEB-101 in the second quarter, having launched an investigator-initiated trial in China.
The Victoria Advocate

GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World's First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational ...

HONG KONG, BEIJING and BOSTON, June 6, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions through ...